When multiple myeloma relapses

RESPOND with the power* of Kyprolis®-based regimens

Treatment may be continued until disease progression or unacceptable toxicity occurs.5‡

*Significant improvement in median PFS with both KRd and Kd regimens.1,2
**Grade ≥ 2.
Comprehensive safety information (across the range of severity, from multiple studies and with different doses) may be found in the SmPC.5 Treatment with the KRd regimen for longer than 18 cycles should be based on an individual benefit–risk assessment (limited data on the tolerability/toxicity of Kyprolis beyond 18 cycles).5

Please read the SmPC for full comprehensive safety information


  1. Stewart AK et al. N Engl J Med 2015;372:142–152.
  2. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.
  3. Dimopoulos MA et al. Presented at the 20th Congress of EHA; 11–14 June 2015; Vienna, Austria. Abstract S427.
  4. Moreau P et al Leukemia 2016;1(1):1–8.

Terms of Use

The information contained in this site is for European healthcare professionals only.